Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
July 31, 2024
July 31, 2024
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
May 14, 2024
May 14, 2024
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Medincell enters into strategic co-development and licensing agreement with AbbVie to develop next-generation long-acting injectable therapies
April 16, 2024
April 16, 2024
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
April 8, 2024
April 8, 2024
MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)
January 31, 2024
January 31, 2024
Teva announces recruitment completion of phase 3 clinical study of mdc-TJK
January 9, 2024
January 9, 2024
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
August 31, 2023
August 31, 2023
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
